Tinos Therapeutics
Cambridge, US · Founded 2023 · Delaware corporation
Tinos Tx develops first-in-class small molecule inhibitors targeting the RNA demethylase FTO to destabilize tumor-driving RNA and kill cancer cells. The company builds on research into how RNA methylation controls cellular survival to create cancer therapeutics.
Founders & leadership
DK
David KarambiziNamed on SEC filing
NT
Nikolaos TapinosNamed on SEC filing
Board
AP
Anastasios PolimenakosBoard director
Reported raises · per SEC filings
Form D private placements$2.3M disclosed across 1 round · 2025
▶$2.3MraisedApr 2026 · 3 investors · BiotechnologyRule 506(b)
▶$2.3MraisedApr 2026 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David KarambiziExecutive Officer, Director
- Anastasios PolimenakosDirector
- Nikolaos TapinosExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $2.3M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Tinos Therapeutics do?
- Tinos Tx develops first-in-class small molecule inhibitors targeting the RNA demethylase FTO to destabilize tumor-driving RNA and kill cancer cells. The company builds on research into how RNA methylation controls cellular survival to create cancer therapeutics.
- How much funding has Tinos Therapeutics raised?
- Tinos Therapeutics has disclosed $2.3M raised across 1 round.
- Where is Tinos Therapeutics headquartered?
- Tinos Therapeutics is headquartered in Cambridge, US.